As expected, US equities welcomed Donald Trump's victory, while European stock markets reacted negatively, also weighed down two days later by a further disappointment on China's stimulus plan. Our sector strategies and baskets of Trump stocks (long or short) have paid off, with a few exceptions that may provide investment opportunities, like Total Energies or Repsol. In Europe, we are maintaining our Underweight recommendation on the Basic Resources, Chemicals, Luxury Goods and Autom...
Comme prévu, les actions américaines ont salué la victoire de Donald Trump tandis que les bourses européennes accusaient le coup, également lestées deux jours plus tard par une nouvelle déception sur le plan de relance chinois. Nos stratégies sectorielles et paniers de valeurs Trump (long ou short) ont fonctionné, avec quelques exceptions qui peuvent être des opportunités d’investissement, à l’instar de Total Energies ou Repsol. En Europe, nous conservons notre opinion Sous-pondérer s...
>Conclusion: New SBB, higher OCG, more cash return clarity, sales was less - It was positive that Aegon announced a new € 150m SBB which we expected, but not all in the market was expecting this we believe. And related to that it is good Aegon announced now to bring the cash at holding down from about est. € 1.66bn end 2024 to about € 1bn end 2026 giving up to € 0.9bn discretionary cash for e.g. new SBB’s over 2025-2026. The Q3 OCG capital generation was better than e...
Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...
>Conclusion: New SBB, Q3 OCG better, higher OCG target, Q3 sales was less - It was positive that Aegon announced a new € 150m SBB which we expected, but not all in the market was expecting this we believe. And related to that it is good Aegon announced now to bring the cash at holding down from about est. € 1.7bn end 2024 to about € 1bn end 2026 giving more room for new SBB’s. The Q3 OCG capital generation was better than expected. The Solvency was marginally less. Th...
AEGON is starting to move more firmly away from its restructuring and legacy books and looks set to embrace a path focusing more on growth, notably in the US, organically and also possibly externally through M&A. Increasing cash generation and fungibility results in Share Buybacks that we now expect to be €300m per annum, but with potential to increase should AEGON decide to lower its cash balance upper end need to €1bn. The ASR stake is finally increasing in value, while new CFO Duncan Russell ...
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
With the recall behind us we believe its time to look forward. Ignoring the noise from the recall over the last years, we believe Philips performance was good. Moreover the company’s positioning in IGT, Monitoring, Cardio Ultrasound and MRI has never been better. There is a credible self-help plan to lift Adj EBITA by 70% over the coming 5 years which should position margins and returns at industry average. The discount to the sector is no longer warranted. We upgrade to outperform. - ...
>Conclusion: Q3 stable solvency and OCG, a new positive SBB possible - Aegon will present a Q3 trading update in which we expect a stable US RBC ratio and a stable UK Solvency ratio by end-Q3 vs end-Q2. The gross cash capital at holding is expected to be € 1.5bn by end-Q3 24, which is at the top end of their target € 0.5-1.5bn range. We expect qoq a stable OCG before holding/interest costs of € 287m in Q3 24. At the trading update it is possible that Aegon would annou...
>Conclusion: 2Q24 OCG in line, Solvency marginally better, negative US mortality - In 2Q24 the OCG capital generation was in line with expectations. End 1H24 the solvency was marginally better than expected in the US. The cash at holding was in line with expectations, and they have not yet announced the reduction of cash at holding target. We expect this to be announced at a later stage. In 1H24 they had negative mortality assumption charges under IFRS, which is posi...
>Conclusion: 2Q24 OCG in line, Solvency marginally better, negative mortality experience/assumption changes, US sales somewhat light - The 2Q24 capital generation and cash at holding was in line with expectations and the US solvency was marginally better. However, in the US they did have some negative mortality experience in the operating result and negative mortality assumption updates in the below the line/other income. The US sales was somewhat light in 2Q24. Aegon...
>Conclusion: Stable H1/Q2 results, might be reduction cash at holding target - For end 2Q24 which we expect a marginal decline of the US RBC solvency and UK Solvency 2 ratio vs end- Q1 24. The gross cash capital at holding is expected to rise marginally to € 2.1bn by end-Q2 24 (€ 1.96bn end-Q1 24) as a result of the dividend upstreamings/income. We expect a stable underlying OCG in Q2 24 vs Q1 24. At the result day Aegon might announce a reduction of the cash at holdi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.